Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Search content at Prinses Máxima Centrum
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Improved endpoints for cancer immunotherapy trials
Axel Hoos
,
Alexander M.M. Eggermont
, Sylvia Janetzki
, F. Stephen Hodi
, Ramy Ibrahim
, Aparna Anderson
, Rachel Humphrey
, Brent Blumenstein
, Lloyd Old
, Jedd Wolchok
Research output
:
Contribution to journal
›
Review article
›
peer-review
498
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Improved endpoints for cancer immunotherapy trials'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Nursing and Health Professions
Immunotherapy
100%
Cancer Immunotherapy
100%
Economic and Social Development
50%
Cancer Research
25%
Neoplasm
25%
Hazard Ratio
25%
Biological Marker
25%
Tumor Volume
25%
Clinical Outcome
25%
Kaplan Meier Method
25%
Response Evaluation Criteria in Solid Tumors
25%
World Health Organization
25%
Chemotherapy
25%
Clinical Trial
25%
Mathematical Model
25%
Immunology and Microbiology
Immunotherapy
100%
Cancer Immunotherapy
100%
Adoptive Immunity
75%
Tumor Volume
25%
Immune System
25%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Immunotherapy
100%
Neoplasm
28%
Solid Malignant Neoplasm
14%
Biological Marker
14%
Chemotherapy Regimens
14%
Immunotherapy Clinical Trial
14%
Phase III Trials
14%
Biochemistry, Genetics and Molecular Biology
Cancer Immunotherapy
100%
Cellular Immunity
75%
Tumor Volume
25%
Immunotherapy Clinical Trial
25%
Phase III Trials
25%
Neuroscience
Immunotherapy
100%
Cancer Immunotherapy
100%
Chemotherapy
25%
Biological Marker
25%
Keyphrases
Novel Endpoints
25%
Immunotherapy Clinical
25%
New Development Model
25%